LRRK2 and Parkinson disease: Should these medical advancements prompt us clinicians taking care of patients with PD to offer routine genetic testing for glucocerebrosidase (GBA) and leucine‐rich repeat kinase (LRRK2) pathogenic variants, as they are the most commonly known PD risk and causal variants and the most targeted in gene‐specific interventional trials?